[GLP-1 agonists reduce the risk of major cardiovascular events in older patients with type 2 diabetes, and SGLT2 inhibitors prevent hospitalizations for acute heart failure]

Recenti Prog Med. 2024 Dec;115(12):604-605. doi: 10.1701/4392.43920.
[Article in Italian]
No abstract available